←
Stephen V Liu, MD23,933 posts
Stephen V Liu, MD avatar

Stephen V Liu, MD

@StephenVLiu

Chief of Hematology & Oncology @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, Thoracic Oncologist #TexasLung27 #DCLung27 #HereWeGo

◷ Joined September 2011▧ 7,939 Photos and videos
Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·3h

Post PACIFIC outcomes @ClinicalLung. Of 190 pts receiving durvalumab consolidation post chemoradiation for NSCLC, 91 patients recurred, mPFS2 7.9m, mOS2 12.1m, and the most common sites of distant spread were brain, bone, and liver. clinical-lung-cancer.com/art…

Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·19h

FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? fda.gov/drugs/cancer-approva…

Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·Nov 17

Post selective TKI outcomes in RET+ NSCLC @CCR_AACR. With subsequent therapy, RR was 41%, rwPFS 5.9m with chemo and 6.8m with chemo + immunotherapy, rwOS 18.5m and 13.7m (p=ns). 3L therapy most often taxanes: rwPFS 1.5m, RR 0%. Huge unmet need remains. aacrjournals.org/clincancerr…

Cure GI Cancers avatar
⟳ Stephen V Liu, MD retweeted
Cure GI Cancers@RueschCenter·Nov 16

Last chance to register for the 17th Annual Ruesch Center Symposium Scientific Day — Friday, November 20th, 2026! Join us for discussion, networking, and debate on critical issues related to GI cancers. bit.ly/Ruesch26. Use Promo Code Guest26 to waive the fee for @MedStarGUH and @LombardiCancer clinicians and researchers. @OncLive

Post attachment
Paolo Tarantino avatar
⟳ Stephen V Liu, MD retweeted
Paolo Tarantino@PTarantinoMD·Nov 16

Celebrating 20 years of @TheTBCRC! A terrific community of investigators bringing innovation to patients and tackling important clinical questions often left unanswered by registrational trials. An impressive track record, with the invaluable support of @SusanGKomen and @BCRFcure: 🔬 74 trials approved 👥 7,700+ participants enrolled 📚 72 peer-reviewed publications 🎤 140+ scientific presentations 💪And much more to come, including 4 oral presentations at #SABCS26! Excited to join @MitchElliott18 as Social Media Co-Chair and help share the incredible research coming from this group! 👉 Follow @TheTBCRC to stay updated!

Post attachment
FiercePharma avatar
⟳ Stephen V Liu, MD retweeted
FiercePharma@FiercePharma·Nov 15

FDA rejects Summit Therapeutics’ ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class fiercepharma.com/pharma/fda-…

Chul Kim avatar
⟳ Stephen V Liu, MD retweeted
Chul Kim@chulkimMD·Nov 14

Fantastic talk by Dr. @jennifermarksmd on emerging targets and therapies in TET: bispecifics, MTAP, VEGF inhibition, and ADCs among others. Encouraging progress in systemic therapy! #ITMIG2026

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·Nov 14

So grateful to all who helped make the MedStar Health Wine and Dine such a big success - including the singular @eunyangnbc and all the amazing people at Four Seasons and Bourbon Steak DC. Coming together to support lung cancer research - such an impactful event. @MedStarHealth

Post attachmentPost attachmentPost attachmentPost attachment
Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·Nov 13

Dr. @PatelOncology provides an updated overview of immunotherapy in early stage NSCLC; compares and contrasts to melanoma. Neoadjuvant and perioperative have been more consistent than adjuvant but many questions remain including approach to borderline resectable cases. #ILCS26

Post attachmentPost attachmentPost attachmentPost attachment
Chul Kim avatar
⟳ Stephen V Liu, MD retweeted
Chul Kim@chulkimMD·Nov 13

ITMIG 2026 Annual Meeting is officially underway in São Paulo! It has been an honor to serve as co-chair and help put this meeting together. My sincere thanks to my co-chair, Dr. Alberto Dela Vega, the Steering Committee, and the Scientific Program Committee for their support.

Post attachmentPost attachment
Stephen V Liu, MD avatar
Stephen V Liu, MD@StephenVLiu·Nov 13

Characterization of MTAP loss (IHC) in NSCLC @CCR_AACR. MTAP loss in 17%. In stage IV, more in driver pos (24%) than driver neg (14%). 64% concordance between lung & lymph nodes. In vitro, variable sensitivity to PRMT5 inhibition (more combined with TKI). aacrjournals.org/clincancerr…